MannaResearch Acquires Montreal Clinical Research Center
MannaResearch, a group of independent clinical research centers, announces the successful acquisition of Kells Medical Research Group, a Montreal-based clinical investigator site.
MannaResearch
, a group of independent clinical research centers, announces the successful acquisition of
Kells Medical Research Group
, a Montreal-based clinical investigator site.
This acquisition represents the fourth Canadian research center MannaResearch has acquired in the past 15 months and its first in Montreal. With more than 15 years of clinical trial experience, Kells Medical Research Group is one of Montreal’s largest primary care research centers and has a database of more than 200,000 patients. The acquisition brings the MannaResearch patient database to 350,000.
Dr. Graham Wood, MannaResearch’s Chief Executive Officer, explains, “Within the industry, the Kells name is synonymous with quality and experience, making the company a perfect fit for MannaResearch. This acquisition represents a strategic addition to our rapidly expanding group of
sites
, helping us attain our goal of simplifying clinical research in Canada for pharmaceutical companies.”
The acquisition supports MannaResearch’s commitment to growth. Over the next few years MannaResearch plans to add additional research sites within Canada to provide its clients access to consistent, high-quality research centers across the nation.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
